November 29, 2016 09:24 AM EST
R&D

Step aside As­traZeneca, Pfiz­er/Mer­ck KGaA jump ahead, get­ting a speedy re­view for their check­point ri­val avelum­ab

John Carroll

Editor & Founder

Now it’s Pfiz­er’s turn to jump in­to the hot­ly con­test­ed check­point mar­ket.

The phar­ma gi­ant and its part­ner Mer­ck KGaA say that the FDA has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times